The Life Sciences and M&A teams advised CK Life Sciences, a member of the CK Hutchison Group, in connection with Virios Therapeutics’ (NASDAQ: VIRI) definitive share exchange agreement with Sealbond Limited, an indirect parent of Wex Pharmaceuticals, pursuant to which the companies will combine in an all-stock transaction. Wex Pharmaceuticals is a wholly owned subsidiary of CK Life Sciences Int’l.
The combined company’s new name will be Dogwood Therapeutics (NASDAQ: DWTX) and it will be focused on the clinical development of three assets: Halneuron®, currently in Phase 2b development for chemotherapy-induced neuropathic pain; IMC-1, poised for Phase 3 development as a treatment for fibromyalgia; and IMC-2, currently in Phase 2 development to treat Long-COVID sequelae.
Virios Therapeutics’ common stock will cease trading under the ticker symbol “VIRI” and will begin trading on the Nasdaq Capital Market under the ticker symbol “DWTX” as of the commencement of trading on October 9, 2024.
CK Life Sciences Int’l., (Holdings) Inc. is listed on The Stock Exchange of Hong Kong Limited. Bearing the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, manufacturing, commercialisation, marketing, sale of, and investment in products and assets which fall into three core categories – nutraceuticals, pharmaceuticals & diagnostics, and agriculture-related. CK Life Sciences is a member of the CK Hutchison Group.
The Goodwin team was led by Blake Liggio, Caitlin Tompkins and Sam Zucker.
For additional details on the agreement, please read the press release.